環球健康 (UHS) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day and thank you for standing by. Welcome to the Q4 2025 Universal Health Services earnings conference call. (Operator Instructions)

    您好,感謝您的耐心等待。歡迎參加 2025 年第四季環球健康服務公司收益電話會議。(操作說明)

  • Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, Darren Lehrich, Vice President of Investor Relations. Please go ahead.

    請注意,今天的會議正在錄影。現在我謹將會議交給今天的演講嘉賓,投資者關係副總裁達倫·萊里奇。請繼續。

  • Darren Lehrich - Vice President, Investor Relations

    Darren Lehrich - Vice President, Investor Relations

  • Good morning and welcome to Universal Health Services fourth quarter 2025 earnings conference call. I'm Darren Lyret, Vice President of Industrial relations. With me this morning are our President and CEO, Marc Miller; and our Chief Financial Officer, Steve Felton. Marc and Steve will provide some prepared remarks, and then we'll open it up to Q&A.

    早安,歡迎參加環球健康服務公司2025年第四季財報電話會議。我是達倫‧萊雷特,工業關係副總裁。今天早上陪同我的還有我們的總裁兼執行長馬克米勒,以及我們的財務長史蒂夫費爾頓。馬克和史蒂夫將發表一些準備好的講話,然後我們將進入問答環節。

  • During today's conference call, we will be using words such as believe, expect, anticipate, estimate, and similar words that represent forecasts, projections, and forward-looking statements. For anyone not familiar with the risks and uncertainties inherent in these forward-looking statements, we recommend a careful reading of the section on risk factors and forward-looking statements and risk factors. In our Form 10-K for the year ended December 31, 2025.

    在今天的電話會議中,我們將使用諸如“相信”、“預期”、“預計”、“估計”等詞語以及代表預測、展望和前瞻性陳述的類似詞語。對於不熟悉這些前瞻性陳述中固有風險和不確定性的任何人,我們建議仔細閱讀有關風險因素和前瞻性陳述及風險因素的部分。在我們截至 2025 年 12 月 31 日的 10-K 表格中。

  • In addition, we may reference during today's call measures such as EBITDA, adjusted EBITDA, adjusted EBITDA net of NCI, and adjusted net income attributable to UHS, which are non-GAAP financial measures. Information and reconciliations of these non-GAAP financial measures to net income attributable to the UHS can be found in today's press release.

    此外,我們可能會在今天的電話會議中提及 EBITDA、調整後 EBITDA、扣除 NCI 後的調整後 EBITDA 以及歸屬於 UHS 的調整後淨收入等指標,這些都是非 GAAP 財務指標。有關這些非GAAP財務指標與歸屬於UHS的淨收入的相關資訊和調節表,請參閱今天的新聞稿。

  • With that, let me now turn it over to Marc Miller for some introductory remarks.

    接下來,我將把發言權交給馬克·米勒,請他作一些開場白。

  • Marc Miller - President, Chief Executive Officer, Director

    Marc Miller - President, Chief Executive Officer, Director

  • Thank you, Darren. Good morning, everybody joining our call. Thank you for your interest in UHS. We closed out 2025 with strong results. Revenue growth for the fourth quarter was 9%. Adjusted EBITA net of NCI increased 10% and adjusted EPS increased 20% as compared to the fourth quarter of 2024.

    謝謝你,達倫。各位早安,正在參加我們通話的各位。感謝您對UHS的關注。2025 年我們取得了強勁的業績。第四季營收成長9%。與 2024 年第四季相比,經調整的 EBITA(扣除 NCI)成長了 10%,經調整的 EPS 成長了 20%。

  • For the full year 2025, revenue growth was 10%, adjusted EBITA net of NCI increased 15%, and adjusted EPS increased 31%.

    2025 年全年,營收成長 10%,扣除 NCI 後的調整後 EBITA 成長 15%,調整後每股盈餘成長 31%。

  • Our fourth quarter and full year performance were highlighted in particular by continued strong expense management in acute care, sequential volume improvements in behavioral health, solid pricing across both segments, and significant share repurchase activity.

    我們第四季度和全年的業績尤其突出,這得益於急性護理方面持續強勁的費用控制、行為健康方面業務量的連續增長、兩個業務板塊的穩健定價以及大量的股票回購活動。

  • Looking back on 2025, I'm very proud of the progress we've made across the organization in several critical areas. We strengthen our growth agenda with the addition of new inpatient capacity, while also intensifying our focus in the outpatient arena through the addition of new service locations across both segments.

    展望 2025 年,我為我們在組織內幾個關鍵領域的進步感到非常自豪。我們透過增加新的住院容量來加強我們的成長計劃,同時透過在兩個領域增加新的服務地點來加強我們對門診領域的關注。

  • We demonstrated financial discipline by managing expenses well in the face of a dynamic operating environment. And we accelerated the pace of technology adoption to improve clinical outcomes and drive greater operating efficiency.

    面對瞬息萬變的經營環境,我們透過有效控制支出,展現了良好的財務紀律。我們加快了技術採用的步伐,以改善臨床結果並提高營運效率。

  • Speaking first to our growth agenda, over the past few years, we've opened two new acute care hospitals and laid the groundwork for significant new acute care capacity to come online during 2026 with three inpatient expansions totaling 178 licensed beds in Florida, California, and Nevada, and a state-of-the-art 156-bed de novo hospital in Palm Beach Gardens, Florida, that will open in the second quarter.

    首先談談我們的成長計劃,在過去幾年裡,我們開設了兩家新的急診醫院,並為2026年新增大量急診護理能力奠定了基礎,包括在佛羅裡達州、加利福尼亞州和內華達州擴建三家住院部,共計178張許可床位,以及在佛羅裡達州棕櫚灘花園市新建一家擁有156張床位的現代季度醫院,將於第二個醫院開業。

  • In our behavioral segment, we've taken a disciplined approach to new bed capacity during 2025 as we've devoted more resources to accelerate our outpatient behavioral strategy. In 2026, we have two behavioral de novo projects totaling 264 beds, including a joint venture project with the Jefferson Health System in Pennsylvania.

    在我們的行為健康領域,我們對 2025 年新增床位採取了審慎的態度,同時投入更多資源來加速我們的門診行為健康策略。2026 年,我們有兩個行為健康新建項目,共 264 張床位,其中包括與賓州傑佛遜健康系統合作的合資項目。

  • On the outpatient side, we operate 119 outpatient behavioral locations, including 10 new freestanding centers opened under our 1,000 branches wellness brand during 2025. We're on track to open at least 10 more branches locations during 2026, and our team continues to pursue opportunities to accelerate our outpatient behavioral growth rate and diversify our segment, payer mix, and service offerings to sustain our leadership position as a provider of choice.

    在門診方面,我們經營 119 個門診行為治療中心,其中包括 2025 年在我們 1000 個分支機構的健康品牌下開設的 10 個新的獨立中心。我們計劃在 2026 年至少再開設 10 家分店,我們的團隊將繼續尋求機會,加快門診行為業務的成長速度,並使我們的業務板塊、支付方組合和服務產品多樣化,以保持我們作為首選服務提供者的領先地位。

  • In terms of expense management, our acute care margins improved in 2025 due to reduced contract labor costs and strong supply chain management performance. Labor productivity also improved through a 2% reduction in same facility acute care length of stay. And this remains an area of opportunity for us in 2026.

    在費用管理方面,由於合約勞動成本降低和供應鏈管理績效強勁,我們的急診照護利潤率在 2025 年有所提高。透過同一機構急性護理住院時間縮短 2%,勞動生產力也提高了。而這在2026年仍然是我們的機會領域。

  • In our behavioral segment, margins were stable in 2025 as compared to 2024, even as we made investments in staffing capacity to relieve some of our labor constraints that have held back our volume growth in certain markets. These investments position us more strongly for volume improvements during 2026.

    在我們的行為細分市場中,儘管我們投資於人員配備能力以緩解某些市場中阻礙我們銷售成長的勞動力限制,但 2025 年的利潤率與 2024 年相比保持穩定。這些投資使我們更有信心在 2026 年實現銷售成長。

  • Finally, from a technology perspective, we've deployed AI and advanced technologies in two primary domains within our business in our operations to impact quality and patient experience, and in our administrative operations to increase efficiency.

    最後,從技術角度來看,我們在業務營運的兩個主要領域部署了人工智慧和先進技術,以影響品質和病患體驗,並在行政營運中提高效率。

  • We have a strong team in place with demonstrated success in evaluating and deploying technology at scale across both acute care and behavioral health divisions. On the operational side we fully rolled out Agentic AI to improve post-discharge care and reduce readmissions.

    我們擁有一支強大的團隊,在急性護理和行為健康部門大規模評估和部署技術方面取得了顯著的成功。在營運方面,我們全面推出了智能體人工智慧,以改善出院後的照護並減少再入院率。

  • In 2026, we are focused on rolling out new patient safety technology and behavioral health, and in acute care, we're deploying AI across several departments and functions to (technical difficulty) and outcomes. On the administrative side, we enhance our QC revenue cycle operations by deploying AI-based solutions to improve documentation and streamline our claims appeals process. Over the next several quarters, we'll be rolling out process improvements and new technologies in our behavioral health revenue cycle operations.

    2026 年,我們將重點介紹新的病患安全技術和行為健康技術,在急診護理方面,我們將在多個部門和職能部門部署人工智慧,以克服技術困難並改善結果。在行政方面,我們透過部署基於人工智慧的解決方案來改善文件並簡化索賠申訴流程,從而增強我們的品質控制收入週期營運。在接下來的幾個季度裡,我們將在行為健康收入周期營運中推出流程改善和新技術。

  • In behavioral health, we are also leveraging AI features and an existing digital tool to streamline the referral and intake process to improve response times to new referrals and improve volumes. In closing, we are optimistic about the future because we continue to invest in our people, our facilities, and in technology that will improve quality, patient experience, and operating efficiency.

    在行為健康領域,我們也利用人工智慧功能和現有的數位工具來簡化轉診和接收流程,以縮短對新轉診的回應時間並提高接診量。最後,我們對未來充滿信心,因為我們將繼續投資於我們的員工、設施和技術,以提高品質、病患體驗和營運效率。

  • With that, I'll now turn the call over to Steve Filton for more details on the quarter and our financial outlook for 2026.

    接下來,我將把電話交給史蒂夫·菲爾頓,讓他詳細介紹本季業績以及我們對 2026 年的財務展望。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Thanks, Mark. I will highlight a few financial and operational trends and outline our 2026 financial guidance before opening the call up to questions. The company reported net income attributable to UHS for diluted share of $7.06 for the fourth quarter of 2025.

    謝謝你,馬克。在開放提問環節之前,我將重點介紹一些財務和營運趨勢,並概述我們 2026 年的財務預期。該公司公佈 2025 年第四季歸屬於 UHS 的稀釋後每股淨收入為 7.06 美元。

  • After adjusting for the impact of the items reflected on the supplemental schedule as included with the press release, our adjusted net income attributable to UHS per diluted share was $5.88 for the quarter end of December 31, 2025.

    在調整了新聞稿附表中所反映的項目的影響後,截至 2025 年 12 月 31 日季度末,歸屬於 UHS 的調整後每股攤薄淨收入為 5.88 美元。

  • During the fourth quarter of 2025, on the same facility basis, adjusted admissions at our acute care hospitals were flat as compared to the fourth quarter of the prior year. Acute care volumes were impacted in part by softness in the Las Vegas market due to factors that we consider somewhat transitory in nature, including lower respiratory case levels on a year over year basis. Excluding the Las Vegas market, our facility acute care volumes would have increased by 1% during the fourth quarter.

    2025 年第四季度,以相同設施計算,我們急性護理醫院的調整入院人數與上年第四季持平。急性照護量受到拉斯維加斯市場疲軟的影響,部分原因是由於我們認為具有一定暫時性的因素,包括呼吸道病例數量較去年同期下降。如果排除拉斯維加斯市場,我們機構的急診護理量在第四季度將成長 1%。

  • Same facility net revenues in our acute care hospital segment increased by 6.9% during the fourth quarter of 2025 on a reported basis as compared to last year's fourth quarter and increased 5.2% after excluding the impact of our insurance subsidiary.

    2025 年第四季度,我們急性護理醫院部門的同店淨收入按報告基準比去年同期增長 6.9%,若不計入保險子公司的影響,則增長 5.2%。

  • Acute care, same facility, revenue per adjusted admission increased by 5.4% during the fourth quarter of 2025. Operating expenses continue to be well managed across labor supplies and other expense categories, excluding the impact of our insurance subsidiary.

    2025 年第四季度,同一機構的急性護理,每次調整入院的收入增加了 5.4%。除保險子公司的影響外,營運費用在勞動力供應和其他費用類別方面繼續得到良好控制。

  • Same facility, acute care salaries, wages and benefits increased 4.4%, and supply expense increased 1.8% over last year's fourth quarter. Same facility contract labor was 2.4% of acute care segment revenue or 20 basis points lower year over year.

    與去年第四季相比,同一機構的急診薪資、薪水和福利增加了 4.4%,供應費用增加了 1.8%。同業拆遷勞動力佔急性護理部門收入的 2.4%,比上年同期下降 20 個基點。

  • For the fourth quarter of 2025, our solid acute care performance resulted in 10.4% growth in same facility segment EBITDA and a 50 basis points improvement in same facility segment EBITDA margin to 14.8%. For the full year, same facility segment EBITDA margin improved 150 basis points to 15.8%.

    2025 年第四季度,我們穩健的急性照護業績使同店 EBITDA 成長了 10.4%,同店 EBITDA 利潤率提高了 50 個基點,達到 14.8%。全年來看,同業拆借利率 (EBITDA) 利潤率提高了 150 個基點,達到 15.8%。

  • Turning to our behavioral health segment results, during the fourth quarter of 2025, same facility net revenues increased 7.2%, supported by a 5.6% increase in same facility revenue per adjusted patient day and a 1.5% increase in same facility adjusted patient days as compared to the fourth quarter of 2024.

    再來看我們的行為健康業務部門業績,2025 年第四季度,同店淨收入增長了 7.2%,這得益於同店每調整患者日收入增長了 5.6%,以及同店調整患者日數增長了 1.5%(與 2024 年第四季度相比)。

  • Expenses in our behavioral health segment increased at a slightly higher pace than revenue due to growth in headcount in certain markets where volumes have been impacted by staffing constraints. For the fourth quarter of 2025, behavioral segment headcount growth was 3.1%. Total same facility labor expense growth, including the increase in headcount, was 7.3% per adjusted day in the US.

    由於某些市場的業務量受到人員配備限制的影響,導致員工人數增加,因此我們行為健康部門的支出成長速度略高於收入成長速度。2025 年第四季度,行為細分領域的員工人數增加了 3.1%。美國同店勞動成本總成長率(包括員工人數增加)為每調整日 7.3%。

  • Overall, we believe expenses were well managed during 2025, leading to total behavioral health segment EBITDA growth of 6.9% in the fourth quarter and 7.8% for the full year 2025.

    總體而言,我們認為 2025 年的支出控制得當,使得行為健康部門的 EBITDA 在第四季度增長了 6.9%,2025 年全年增長了 7.8%。

  • Cash generated from operating activities was $1.9 billion for the 12 months ended December 31, 2025 as compared to $2.1 billion during 2024. Cash flows during 2025 were impacted by $50 million related to an increase in receivables at our two most recent de Novo hospitals and $145 million related to the timing of payments for certain Medicaid supplemental programs.

    截至 2025 年 12 月 31 日的 12 個月,經營活動產生的現金為 19 億美元,而 2024 年同期為 21 億美元。2025 年的現金流量受到以下因素的影響:5,000 萬美元,與我們最近兩家新建醫院的應收帳款增加有關;1.45 億美元,與某些醫療補助補充計劃的付款時間有關。

  • During 2025, we spent $1 billion on capital expenditures, approximately 35% of which related to the De Novo Hospital in Florida and major expansions in Florida and California. During 2025, we also acquired 4.65 million of our shares at a total cost of $899 million, including 1.46 million shares purchased during the fourth quarter of 2025.

    2025 年,我們在資本支出方面花費了 10 億美元,其中約 35% 與佛羅裡達州的 De Novo 醫院以及佛羅裡達州和加州的重大擴建項目有關。2025 年,我們也以 8.99 億美元的總成本收購了 465 萬股股份,其中包括 2025 年第四季購買的 146 萬股股份。

  • At December 31, 2025, we had $1.425 billion of repurchase authorization available pursuant to our stock buyback program, and we had approximately $900 million in aggregate available borrowing capacity pursuant to our $1.3 billion revolving credit facility.

    截至 2025 年 12 月 31 日,根據我們的股票回購計劃,我們有 14.25 億美元的回購授權可用;根據我們 13 億美元的循環信貸額度,我們總共有約 9 億美元的可用借款能力。

  • Turning to our outlook for 2026, we expect revenue to range between $18.4 billion and $18.8 billion, representing growth of 6% to 8%. We expect adjusted EBITDA net of NCI to range between $2.64 billion and $2.79 billion, representing growth of 2% to 8%.

    展望 2026 年,我們預計營收將在 184 億美元至 188 億美元之間,成長 6% 至 8%。我們預計扣除非上市公司權益後的調整後 EBITDA 將在 26.4 億美元至 27.9 億美元之間,成長 2% 至 8%。

  • We expect adjusted net income attributable to UHS for diluted share to range between $22.64 and $24.52 representing growth of 4% to 13%.

    我們預計歸屬於 UHS 的調整後稀釋後每股淨收入將在 22.64 美元至 24.52 美元之間,成長 4% 至 13%。

  • Our guidance assumes same facility volume growth to be in a range of 2% to 3% for both segments for the full year 2026, although it's likely we'll be below this range during the first quarter due primarily to the winter storms, which we are currently assessing in our behavioral health segment and the Washington DC operations of our acute care segments.

    我們的預期是,2026 年全年兩個業務部門的同店營業額成長率將在 2% 至 3% 之間,儘管由於冬季風暴的影響,我們第一季的成長率可能會低於這個範圍。我們目前正在評估冬季風暴對我們行為健康業務部門和華盛頓特區急性護理業務部門的影響。

  • We expect capital expenditures in 2026 to range between $950 million and $1.1 billion, reflecting the culmination of spending for several large inpatient projects that will come online during the first half of 2026.

    我們預計 2026 年的資本支出將在 9.5 億美元至 11 億美元之間,這反映了幾個大型住院計畫在 2026 年上半年投入營運後支出的最終結果。

  • Our guidance includes several assumptions unique to the 2026 operating environment as follows. We assume an adverse pre-tax earnings impact of approximately $75 million related to reductions in the health insurance exchanges. We assume that exchange volumes will decline by 25% to 30%, and approximately 10% to 20% of this volume will shift to other forms of coverage, with the vast majority shifting to self-pay or uninsured.

    我們的指導意見包含以下針對 2026 年營運環境的幾個獨特假設。我們假設醫療保險交易市場的萎縮將對稅前收益產生約 7,500 萬美元的不利影響。我們預計保險交易量將下降 25% 至 30%,其中約 10% 至 20% 的交易量將轉向其他形式的保險,而絕大多數人將轉向自費或無保險。

  • The exchange headwind is concentrated in our acute care segment based on historical utilization patterns. For the full year 2025, exchanges represented approximately 6% of acute care segment adjusted admissions, and slightly less than 5% of the segment's revenue.

    根據歷史使用模式來看,交易所面臨的不利因素主要集中在我們的急診護理領域。2025 年全年,交易所約佔急性護理部門調整入院人數的 6%,以及該部門收入的略低於 5%。

  • We expect a negative pre-tax earnings impact of approximately $35 million in our behavioral segment associated with the recently enacted California inpatient psychiatric hospital staffing regulations that will go into effect on June 1, 2026. The regulation is expected to increase labor costs due to the need to adjust the mix of licensed nursing staff at our facility.

    我們預計,由於加州最近頒布的住院精神病院人員配置規定將於 2026 年 6 月 1 日生效,我們的行為健康業務部門的稅前收益將受到約 3,500 萬美元的負面影響。由於需要調整本院持證護理人員的組成,該規定預計將增加勞動成本。

  • Our 2026 estimate includes a higher burden of recruiting and training costs and some short-term census disruption as our California operations ramp up to comply with the regulations. Beyond 2026, the ongoing costs are expected to be approximately $30 million after considering a full year of higher labor costs.

    我們對 2026 年的預測包括更高的招聘和培訓成本負擔,以及由於我們在加州的業務正在擴大規模以遵守相關規定而導致的一些短期人口普查中斷。2026 年以後,考慮到全年更高的勞動成本,預計持續成本約為 3,000 萬美元。

  • Our 2026 outlook assumes a total net benefit from Medicaid supplemental payments of $1.36 billion and includes a new Nevada supplemental program that was approved this month but does not include any other new programs pending approval.

    我們對 2026 年的展望假設醫療補助補充支付的總淨收益為 13.6 億美元,其中包括本月批准的內華達州新補充計劃,但不包括任何其他正在等待批准的新計劃。

  • As compared to 2025, we expect the net benefit for Medicaid supplemental payments to increase by approximately $23 million. Our 2026 outlook assumes approximately $50 million of favorability related to improvements at Cedar Hill. We assume that incremental improvements we expect to make at Cedar Hill beyond the breakeven level will be offset by startup costs associated with our De Novo Hospital in Palm Beach Gardens.

    與 2025 年相比,我們預計 Medicaid 補充支付的淨收益將增加約 2,300 萬美元。我們對 2026 年的展望假設 Cedar Hill 的改進將帶來約 5000 萬美元的利多。我們假設,我們在 Cedar Hill 預期實現的超出盈虧平衡水平的增量改進,將被我們在 Palm Beach Gardens 新建醫院的啟動成本所抵消。

  • Finally, we expect a favorable pre-tax earnings impact of approximately $50 million comprised of three smaller and discrete items, including a one-time legal settlement recognized in 2025 that we do not expect to reoccur.

    最後,我們預計稅前收益將受到約 5,000 萬美元的有利影響,其中包括三個較小且獨立的項目,例如 2025 年確認的一次性法律和解金,我們預計該和解金不會再次發生。

  • Operational improvements in our Nevada health plan with revenue growth at similar levels as in 2025, and modest contributions from behavioral segment M&A completed in 2025. Primarily in the UK.

    內華達州健康計畫的營運得到改善,收入成長與 2025 年的水平相當,2025 年完成的行為健康領域併購也做出了適度貢獻。主要在英國。

  • In conclusion, we're pleased to share a positive growth outlook for 2026, which assumes core growth from our consolidated operations of approximately 5%, underpinned by the strength of our markets, continued expense management, and ongoing efficiency opportunities.

    總而言之,我們很高興分享 2026 年的積極成長前景,該前景假設我們合併業務的核心成長率約為 5%,這得益於我們市場的強勁表現、持續的費用控制以及不斷提高效率的機會。

  • Operator, that concludes our prepared remarks, and we're pleased to answer questions at this time.

    接線員,我們的發言到此結束,現在我們很樂意回答大家的問題。

  • Operator

    Operator

  • Thank you. (Operator Instructions) AJ Rice, UBS.

    謝謝。(操作說明)AJ Rice,瑞銀集團。

  • AJ Rice - Analyst

    AJ Rice - Analyst

  • Thanks everybody.

    謝謝大家。

  • Yeah, two things. First of all, just to drill down a little bit more on the guidance for '26, I know you mentioned 2% to 3% volume growth across both the segments. Give us, any flavor on what's embedded in pricing. Are you, is it more of the same what you saw this year across the two segments? Are you assuming, any change in manage care rates or whatever?

    是的,兩件事。首先,為了更深入了解 2026 年的業績指引,我知道您提到兩個細分市場的銷售量都將成長 2% 到 3%。請告訴我們定價包含了哪些因素。你覺得,今年這兩個板塊的情況是否與往年大同小異?您是指醫療管理費率或其他方面有任何變化嗎?

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Sure, so, AJ, I mean, I think, on the acute side our guidance implies a 3% to 4% pricing increase, that's in line if you look at sort of the 10 year average of pricing increase in acute care, I think it's average right around 4%.

    當然,AJ,我的意思是,我認為,在急性護理方面,我們的指導意見意味著價格上漲 3% 到 4%,如果你看一下急性護理價格上漲的 10 年平均值,我認為這是一致的,我認為平均漲幅在 4% 左右。

  • And I think that's, continues to be, where that pricing is supported by a steady increase in acuity over that period that we expect will continue, on the behavioral side we're expecting pricing in the sort of 2% to 3% range. And we acknowledge that that's, somewhat lower than we've been running for the last several years, as we've been expecting that price, a really strong pricing of the last several years to begin to moderate at some point as these increased. Contract prices have, begun the anniversary, etcetera and I think we're starting to see that evidence. So slightly, lower pricing expected in, April compared to the last several years, but I think also again in line with historical rates.

    我認為,在預期這段期間內,市場敏銳度的穩定提升將持續支撐價格,而從行為來看,我們預期價格漲幅將在 2% 到 3% 之間。我們承認,這個價格比過去幾年的水平要低一些,因為我們一直預期,過去幾年非常強勁的價格會隨著這些因素的增加而開始趨於緩和。合約價格已經開始進入周年紀念日等等,我認為我們已經開始看到這種跡象了。因此,預計4月份的價格將比過去幾年略有下降,但我認為這也與歷史價格基本一致。

  • AJ Rice - Analyst

    AJ Rice - Analyst

  • Okay, and I appreciate all the comments, that Mark offered on the AI applications, and it does seem like hospitals and health systems are. AI rich environment for our opportunities. The question I get asked it's not an easy one, but, how do you think about how that translates into, operating performance in terms of, the financial impact of those applications and over what time frame, might we start to see that have an impact on, revenues or margins, those type of things that you're calling out.

    好的,我很感謝 Mark 對人工智慧應用提出的所有意見,醫院和醫療系統似乎確實正在應用人工智慧。人工智慧豐富的環境為我們提供了機會。我經常被問到這個問題,這並不容易回答,但是,您如何看待這些應用程式對營運績效、財務影響以及在多長時間內可能開始對收入或利潤率等您提到的方面產生影響。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, so I think, as Mark described in his comments, AJ, we have focused, and I certainly believe we like most are in the early innings of this, AI game. I think, our initial efforts have really focused on. Administrative, sort of efforts like within our revenue cycle management, I think Mark, alluded to, claims appeals and coding and, we've used that, I think, to, great effectiveness. I think, really what we're doing, and, other, otherwise, I think you also referred to, post-discharge activity.

    是的,所以我覺得,正如馬克在他的評論中所描述的那樣,AJ,我們已經專注於此,而且我當然相信我們和大多數人一樣,還處於這場人工智慧遊戲的早期階段。我認為,我們最初的努力確實集中在以下方面。行政方面的努力,例如在我們的收入週期管理中,我認為馬克也提到了索賠申訴和編碼,而且我認為我們已經有效地利用了這些努力。我認為,我們真正正在做的,以及其他方面,我想你也提到了,出院後的活動。

  • So historically a nurse would make a post-discharge follow-up phone call, with a patient to ensure they're being compliant with their, medications and, their diet and follow-up with appointments with a physicians, and, now we're using an AI agent to make those calls in many cases.

    因此,過去護理師會在患者出院後進行追蹤電話,以確保他們遵醫囑服藥、注意飲食,並按時復診。而現在,我們在許多情況下都使用人工智慧代理來撥打這些電話。

  • And so, in both. Cases I think we're driving efficiencies, it allows us to reduce head count, it improves the outcomes as measured by, revenue [cycletrics] or, reduction in readmissions which I think Mark alluded to. So again, I think it's impossible to precisely quantify, even precisely quantify what we've been able to achieve, but certainly precisely difficult to precisely quantify what the opportunities may be, but we think they're significant.

    所以,兩者都是如此。我認為我們正在提高效率,這使我們能夠減少人員數量,並改善結果,例如收入(週期)或再入院率的降低,我認為馬克也提到了這一點。所以,我認為我們不可能精確量化,甚至不可能精確量化我們已經取得的成就,更不可能精確量化可能的機會,但我們認為這些機會意義重大。

  • AJ Rice - Analyst

    AJ Rice - Analyst

  • Okay, thanks a lot.

    好的,非常感謝。

  • Operator

    Operator

  • Thank you. Ann Hynes, Mizuho Securities

    謝謝。安海恩斯,瑞穗證券

  • Ann Hynes - Analyst

    Ann Hynes - Analyst

  • Great, thank you. Within your acute care volumes of 2% to 3%, can you let us know what you're assuming surgical volume versus medical volume and then with the Nevada market, how did that market do in 2025 and how do you expect it to grow in 2026?

    太好了,謝謝。在您2%到3%的急性照護量中,能否告知我們您假設的手術量與醫療量分別為何?另外,內華達州市場在2025年的表現如何?您預計它在2026年將如何成長?

  • Thank you.

    謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • And so I think surgical volume in 2025, lagged our overall by a slight amount. It was positive. Our surgical volume growth in Q4 was positive over last year's fourth quarter, so, we're encouraged by that. I think that.

    因此,我認為 2025 年的手術量將略低於我們的整體水準。結果為陽性。我們第四季的手術量成長比去年同期有所成長,這讓我們感到鼓舞。我覺得是這樣。

  • Our, expectations for next year are somewhat similar that, surgical volumes probably don't grow quite as fast as our overall volumes, but I think I sync up pretty closely, as far as Nevada goes, I think Nevada. In 2025 has grown in line with the rest of the acute division. I think, historically that market has tended to grow faster. It was a little bit challenging in 2025.

    我們對明年的預期與此類似,手術量可能不會像我們的整體業務量那樣快速增長,但我認為我的預期與內華達州的整體業務量增長相當接近。2025 年的成長與急性病科其他部門的成長保持一致。我認為,從歷史數據來看,這個市場往往成長得更快。2025年有點挑戰性。

  • There's been, much reporting of, tourist volumes and, tourist activity in Las Vegas being down in 2025, and that's impacted us, I think, to a small degree. We don't get a lot of. Patient activity directly from the tourist population, but obviously it has a cascading effect. We're encouraged by the fact, however, that employment, trends have remained, quite stable in Las Vegas, and that historically has been the leading indicator of sort of how we're going to do and how the economy is going to do there.

    有許多報導稱,2025 年拉斯維加斯的遊客數量和旅遊活動將會下降,我認為這在一定程度上影響了我們。我們不常有。患者活動直接來自遊客群體,但顯然會產生連鎖反應。不過,令人鼓舞的是,拉斯維加斯的就業趨勢一直保持相當穩定,而從歷史上看,就業一直是衡量我們未來發展以及當地經濟走向的重要指標。

  • And so, and, the casino or gaming industry reports, I think, pretty bullish prospects for their, 2026 convention and conference booking. So, we're assuming that the Vegas market, experiences a bit of an uptick in 2026.

    因此,我認為,賭場或博彩業報告稱,他們對 2026 年的會議和會展預訂前景相當樂觀。因此,我們假設拉斯維加斯市場在 2026 年會出現小幅回升。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Justin Lake, Wolfe Research.

    賈斯汀·萊克,沃爾夫研究公司。

  • Justin Lake - Analyst

    Justin Lake - Analyst

  • Hi, thanks, this is Ann on for Justin. Can you share what you're seeing on exchange volume so far, given there's a significant number of members that haven't paid their premiums yet? And I know that in Feb, March the plans don't have to pay the provider on members that don't pay premiums. Are you able to see this information from plans and what's your level of visibility on the potential bad debt here? Thanks.

    您好,謝謝,我是安,替賈斯汀報到。鑑於目前仍有相當一部分會員尚未繳交會費,您能否分享一下您目前觀察到的交易量情況?我知道在二月和三月,保險計劃不必向不繳納保費的會員支付費用。您能否從計劃中看到這些資訊?您對潛在的壞帳了解程度如何?謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, and so, as I said in our prepared remarks, we're assuming a 25% to 30% decline in exchange volumes.

    是的,正如我在事先準備好的演講稿中所說,我們預計交易量將下降 25% 至 30%。

  • That's largely based on CBO and other sort of public projections. We've seen, we've already seen a decline in exchange volumes in, the first couple of months of the year. I don't think quite to that extent, but I think as your, question alludes to, we believe that, some of the early reporting on how much exchange volume has been lost is understated because, the insurance companies won't report exchange volumes down until people start to miss premiums, etc.

    這主要依據國會預算辦公室和其他公開機構的預測。我們已經看到,今年前幾個月的交易量出現了下降。我不認為會達到那種程度,但正如你的問題所暗示的那樣,我們認為,一些關於交易量損失的早期報道被低估了,因為保險公司只有在人們開始拖欠保費等情況下才會報告交易量下降。

  • So. Yeah, I mean, and that's a challenge for us because we are in the position sometimes of verifying a patient's insurance with the payer, and, the payer, verifying their insurance, and then when we build the pay, bill the payer comes back to us and says the premiums haven't been paid and they don't pay, they won't reimburse the charges at that point. That has always been a risk for us. Obviously it'll be an increased risk. In this period where there's a dramatic decline in exchange volumes, but we believe that we've accounted for that in our assumptions.

    所以。是的,我的意思是,這對我們來說是個挑戰,因為我們有時需要向付款方核實患者的保險信息,付款方也需要核實他們的保險信息,然後當我們計算付款、開具賬單時,付款方卻告訴我們保費尚未支付,他們不支付,所以他們不會在這個時候報銷費用。這對我們來說一直是個風險。顯然,這會增加風險。雖然目前交易量急劇下降,但我們相信我們已經在假設中考慮到了這一點。

  • But I think, one of the things we all of us, meaning all the hospital companies have made estimates about. What's going to happen with the exchanges, etc. But the truth is, we're going to need a few more months to really see how this sorts out, what the real loss in volume is, how many of these people who lose their exchange coverage can get other coverage, etc. So we've made our best estimates, we feel comfortable with the estimates we've made, but I think, we're all going to become, be able to be more precise, over the next few months as we get more and more accurate data.

    但我認為,我們所有人,也就是所有醫院公司,都對其中一件事做出了估計。至於交易所會發生什麼事等等,目前還不得而知。但事實上,我們還需要幾個月的時間才能真正了解情況,看看實際的交易量損失是多少,有多少失去交易所保險的人能夠獲得其他保險等等。所以我們已經做出了最佳估計,我們對這些估計感到滿意,但我認為,隨著我們獲得越來越多準確的數據,在接下來的幾個月裡,我們都能做出更精確的預測。

  • Operator

    Operator

  • Thank you. Andrew Mok, Barclays.

    謝謝。Andrew Mok,巴克萊銀行。

  • Andrew Mok - Analyst

    Andrew Mok - Analyst

  • Hi, good morning, Steve, you mentioned a $35 million headwind from the new California behavioral staffing requirement for 2026 but also noted a $30 million annual ongoing impact. Can you give us a bit more detail on the nature of the headwind and help us understand why, the headwind from the mid-year implementation wouldn't annualize into a larger run rate headwind? Thanks.

    嗨,早安,史蒂夫,你提到加州新的行為人員配備要求在 2026 年會帶來 3500 萬美元的不利影響,但也指出每年會產生 3000 萬美元的持續影響。您能否更詳細地說明不利因素的性質,並幫助我們理解為什麼年中實施帶來的不利因素不會演變成更大的年度運行率不利因素?謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Sure, so, Andrew, the task before us is that the new California staffing requirements don't necessarily require us to increase our headcount overall. I think actually we have. In excess of the head count that that they're requiring, but it is a different mix of staff and is more heavily skewed to licensed, professionals, particularly RNs. So, we're going to have to change our staffing models in, a number of our facilities. We will hire more RNs. We think that there is some sort of upfront, investment in doing that, potentially startup costs, increased recruiting costs, etc.

    當然,安德魯,我們面臨的任務是,加州新的員工配備要求並不一定要求我們增加員工總數。我認為我們實際上已經有了。雖然人數超過了他們要求的人數,但員工組成有所不同,持證專業人員的比例更高,尤其是註冊護士。因此,我們將不得不改變我們一些設施的人員配備模式。我們將招募更多註冊護士。我們認為這樣做需要一些前期投資,可能包括啟動成本、增加招募成本等等。

  • There might be, I think, as I indicated in my prepared remarks, in the first couple of months, we may not have all the slots filled and therefore we're anticipating, potential short-term volume disruption. But once we are fully staffed, which we think we will be at some point in 2026, then I think the ongoing costs, are reduced, and we won't have those startup and sort of I'll call investment in infrastructure investment costs duplicated in 2027 and beyond, which is why. The annual impact in 2027 and beyond or the expected annual impact is actually a little bit less than what we're expecting for a partial year of the regulations in 2026.

    我認為,正如我在準備好的演講稿中所述,在最初的幾個月裡,我們可能無法填滿所有名額,因此我們預計可能會出現短期銷售中斷的情況。但一旦我們人員配備齊全(我們認為這將在 2026 年的某個時候實現),我認為持續成本就會降低,我們就不會在 2027 年及以後重複承擔啟動成本和基礎設施投資成本,這就是原因。2027 年及以後的年度影響或預期年度影響實際上比我們對 2026 年部分年份法規的預期影響要小一些。

  • Operator

    Operator

  • Thank you. Ben Hendrix, RBC Capital Markets

    謝謝。本‧亨德里克斯,加拿大皇家銀行資本市場

  • Ben Hendrix - Analyst

    Ben Hendrix - Analyst

  • Thank you very much and good morning. We've heard carriers talk a lot about accelerated behavioral trend for a while now, and it sounds like your outpatient development is addressing that. Can you talk a little bit more about where the demand is on the outpatient behavioral side in terms of the. Types of services and the types of services that are being offered in the development you completed in 2025 and what do you expect for 2026 and then how we should we think about the optimal behavioral business mix over the long-term between the inpatient and outpatient.

    非常感謝,早安。我們已經聽到保險公司談論加速行為趨勢一段時間了,聽起來你們的門診發展計畫正在解決這個問題。能否再詳細談談門診行為治療的需求?您在 2025 年完成的開發案中提供的服務類型有哪些?您對 2026 年有何預期?從長遠來看,我們應該如何考慮住院和門診之間最佳的行為業務組合?

  • Thanks.

    謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, Ben, let me, answer this is Marc. So you know our our outpatient strategy continues to progress right now, outpatient services represent about 10%. Of our behavioral segment revenue, we expect that to continue to grow, as I said on the prepared remarks, we already operate, close to 120 outpatient locations where we offer either step down services or step in services. So for the step down locations. We have transitional services such as partial hospitalization, intensive outpatient, following an acute care, an acute psychiatric t.

    是的,本,讓我來回答,我是馬克。所以你知道,我們的門診策略仍在持續推進,門診服務約佔10%。我們預計行為健康業務的收入將繼續增長,正如我在準備好的演講稿中所說,我們已經運營了近 120 個門診地點,提供過渡服務或過渡入院服務。所以,對於下行位置來說。我們提供過渡服務,例如部分住院治療、強化門診治療、急性照護後的治療、急性精神病治療等。

  • And we typically operate these locations and their satellite clinics under our local brand of our inpatient facilities, and they're often close to those facility campuses. The step-in services are for patients entering the behavioral system on an outpatient basis, so people that we've not even had yet as inpatient. The payers continue to look for in-network providers with scale to offer these types of step-in services, as an alternative to inpatient care. So we think our step-in model offers comprehensive outpatient services which would include things like IOP counseling, virtual care.

    我們通常以我們本地品牌的住院機構來經營這些地點及其衛星診所,而且它們通常靠近這些機構的院區。過渡服務是為以門診方式進入行為健康系統的患者提供的,也就是我們還沒有收治過的住院患者。支付方繼續尋找有規模的網路內醫療服務提供者,以提供此類過渡性服務,作為住院治療的替代方案。因此,我們認為我們的介入模式提供了全面的門診服務,其中包括 IOP 諮詢、虛擬護理等。

  • And we think the demand for that's going to only, continue to grow in 2026. In a number of markets we've now branded this, under what we're calling 1,000 branches wellness, thus far, we, we're in development and we expect to open at least 10. Of these branches locations in 26, so I think that we have, a good ramp up already planned, and we expect that there's going to be many more opportunities to expand in all of these areas, going forward.

    我們認為,到 2026 年,對這種產品的需求只會繼續增長。在一些市場,我們已經將此品牌命名為“1000家分店健康計劃”,目前我們正在開發中,預計將至少開設10家分店。這些分支機構分佈在 26 個地點,所以我認為我們已經制定了良好的擴張計劃,並且我們預計未來在所有這些地區都會有更多擴張的機會。

  • Ben Hendrix - Analyst

    Ben Hendrix - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. Stephen Baxter, Wells Fargo.

    謝謝。史蒂芬‧巴克斯特,富國銀行。

  • Stephen Baxter - Analyst

    Stephen Baxter - Analyst

  • Yeah, hi, thank you. Just wanted to follow-up on, California for a couple of points there, I guess as you're kind of building up to that, long-term $30 million run rate impact, does that really just reflect the kind of the changes directly on the incremental staffing side, or are you thinking that there could be any spillover impacts to. Your base wage structure potentially related to maybe your consumer or your competitors trying to, maybe hire in the same way that you are and then as you think about, potential reimbursement in California I know California budgets are not exactly flushed at the moment, but is there any prospect for potentially seeing any offset on the reimbursement side anywhere in the near future?

    是啊,你好,謝謝。我只是想就加州的情況再補充幾點,我想說的是,你們正在逐步推算出長期 3000 萬美元的運行率影響,這真的僅僅反映了新增人員方面的直接變化,還是你們認為可能會有任何溢出效應?您的基本工資結構可能與您的消費者或競爭對手試圖以與您相同的方式招聘有關,然後當您考慮加州的潛在報銷時,我知道加州目前的預算並不充裕,但在不久的將來,是否有可能在報銷方面看到任何抵消措施?

  • Thank you.

    謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, so Stephen, I think you know our again assumptions were, the cost of replacing, current staff with a higher license and we acknowledge certainly as we went through this exercise that.

    是的,史蒂芬,我想你知道我們之前的假設是,用更高資質的執照替換現有員工的成本,而且我們在進行這項工作的過程中也承認這一點。

  • All acute behavioral facilities in California would have to be going through the same exercise. So we did our best to project what wage inflation might be and what, might be required in terms of recruitment incentives and that sort of thing. Obviously, this is new to all of us and so, we, we're we're making certain guesses and estimates, but we think we've been reasonably conservative in our approach.

    加州所有急性行為障礙治療機構都必須經歷相同的流程。因此,我們盡力預測薪資通膨可能會如何,以及在招聘激勵措施等方面可能需要採取哪些措施。顯然,這對我們所有人來說都是全新的,所以我們只能做出一些猜測和估計,但我們認為我們採取的方法相當保守。

  • Again acknowledging that others will be going through the same process as us as far as reimbursement goes, your point is well taken. We will certainly make every effort to work with all of our payers, whether they be government payers, the.

    再次承認其他人也會經歷和我們一樣的報銷流程,你的觀點很有道理。我們一定會盡一切努力與所有付款方合作,無論是政府付款方還是其他付款方。

  • The medical program in California or you know our private commercial payers to get them to acknowledge this increased cost on our part you know how that will sort out ultimately I don't know we we certainly have not forecast or budgeted anything for that but we will certainly you know focus our efforts on that.

    加州的醫療計劃,或者說我們的私人商業保險公司,要讓他們承認這會增加我們的成本,你知道最終會如何解決,我不知道,我們當然沒有對此進行預測或預算,但我們肯定會把精力集中在這方面。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Jason Cassorla, Guggenheim Partners

    傑森卡索拉,古根漢合夥公司

  • Jason Cassorla - Equity Analyst

    Jason Cassorla - Equity Analyst

  • Great, thanks. Good morning. Maybe just stepping back, for behavioral, you're expecting accelerating volumes, but, a bit of deceleration in pricing growth. I guess if you look at that 2% to 3% volume and 2% to 3% rate growth as the go forward status quo, would you still expect that to translate. Into organic margin expansion or has that equation changed in terms of how you think about margin expansion for that business? Thanks.

    太好了,謝謝。早安.或許退一步來看,從行為角度來看,你預期銷售量會加速成長,但價格成長會略為放緩。我想,如果你把 2% 到 3% 的銷售量和 2% 到 3% 的利率成長視為未來的現狀,你還會期望這種情況持續下去嗎?是朝著有機利潤率擴張的方向發展,還是說你對這家企業利潤率擴張的看法已經改變了?謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, so obviously those assumptions, 2% to 3% patient day or adjusted patient day growth, 2% to 3% pricing growth result in 4% to 6%, a 4% to 6% revenue growth projection, we think generally that revenue growth level will exceed, the level of, the increase in operating costs, and we made the point in our operating, excuse me, in our prepared remarks that in 2025.

    是的,顯然這些假設,即患者日或調整後患者日增長 2% 至 3%,價格增長 2% 至 3%,將導致 4% 至 6% 的收入增長預測,我們認為,總體而言,收入增長水平將超過運營成本的增長水平,我們在運營方面,抱歉,在我們準備好的發言中指出,到 2025 年。

  • Our operating costs were a little bit elevated, by, kind of an investment in headcount and hiring and filling vacant positions in markets where, that has been a headwind or an obstacle to, reaching our targeted volume growth. I think that, headcount, increase will clearly moderate in 2026.

    我們的營運成本略有上升,這主要是因為我們投資於人員配備,並在那些阻礙我們實現預期銷售成長的市場中招募和填補空缺職位。我認為,到 2026 年,員工人數的成長速度將明顯放緩。

  • And leave us at a point where I think, wage inflation and other operating cost inflation, should not necessarily exceed, the growth in the growth in revenue which, will allow for a margin expansion, and then I would just also add, following on to, Marc's comments about the growth in outpatient. Generally outpatient margins are better than inpatient margins, so to the degree that we're successful in, growing the outpatient business faster than inpatient, that should also help, margin expansion in behavioral.

    最後,我認為薪資上漲和其他營運成本上漲不應超過收入成長,這樣才能實現利潤率擴張。此外,我還要補充一點,正如馬克之前關於門診成長的評論。一般來說,門診利潤率高於住院利潤率,因此,如果我們能夠成功地使門診業務的成長速度超過住院業務,那麼這也有助於行為健康領域的利潤率擴張。

  • Jason Cassorla - Equity Analyst

    Jason Cassorla - Equity Analyst

  • Great, thanks. And if I could follow-up just quickly, wanted to ask, about the acute length of stay opportunity you flagged it a little bit in the prepared remarks, it's it looks like length of stay has been coming down a little bit, still slightly above pre-pandemic levels. Case mix has been rising that probably offsets a little bit, but. Maybe can you just help a little bit more unpack in terms of AI technology or other efficiencies that could bring that stat lower and drive better throughput just anything more on the length of stay would be helpful thanks.

    太好了,謝謝。如果可以的話,我想快速追問一下,關於您在準備好的發言稿中稍微提到的縮短住院時間的機會,看起來住院時間似乎有所下降,但仍略高於疫情前的水平。病例組合的上升可能會稍微抵消一部分影響,但是。您能否再詳細解釋一下人工智慧技術或其他可以降低該統計數據並提高吞吐量的效率方面的資訊?關於停留時間的任何補充都將有所幫助,謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, so a couple of observations, Jason, I mean, one is, I think on an acuity adjusted basis, and I think that's the appropriate way to look at length of stay because the sicker a patient is, the longer they're going to have to be in the hospital, but on an acuity, adjusted basis, LOA is actually LOS is actually below, pre-pandemic levels, and I think reflects, improvements that we've made.

    是的,Jason,我有幾點看法。首先,我認為應該根據病情嚴重程度來調整住院時間,我認為這是看待住院時間的合適方法,因為病人病情越重,住院時間就越長。但是,根據病情嚴重程度調整後,實際住院時間實際上低於疫情前的水平,我認為這反映了我們所取得的進步。

  • And you make the point. I mean, there's all kinds of, I think, reporting, opportunities, there, technology opportunities, better communication with our physicians, but honestly, I think probably the single biggest, obstacle we faced in. In not reducing length of stay further is the supply of sub-acute capacity, whether that's in skilled nursing facilities, nursing homes, long-term rehab facilities, etc. There's been, I think, a lack or a dearth of capacity in many markets, in those areas, and, sometimes we're just holding patients. Waiting for an available bed or an available spot. We think that will improve over time and we'll continue to improve, so along with our own internal initiatives, we think the marketplace for, first off, acute capacity will also expand.

    你說的有道理。我的意思是,我認為有很多方面的機會,例如報道、技術方面的機會,以及與醫生進行更好溝通的機會,但說實話,我認為我們面臨的最大障礙可能是…未能進一步縮短住院時間的原因在於亞急性照護能力的不足,無論是專業照護機構、療養院、長期復健機構等等。我認為,在許多市場和這些地區,都存在著照護能力不足或匱乏的問題,有時我們只能讓病人滯留在院內。等待空床位或空位。我們認為這種情況會隨著時間的推移而改善,我們也會繼續改進,因此,除了我們自己的內部措施之外,我們認為首先,急診護理能力的市場也會擴大。

  • Operator

    Operator

  • Thank you. Matthew Gilmore, KeyBanc.

    謝謝。Matthew Gilmore,KeyBanc。

  • Matthew Gillmor - Equity Analyst

    Matthew Gillmor - Equity Analyst

  • Hey, thanks for the question. I want to ask about the Medicaid supplementals. We appreciate the transparency you all provide. For the programs that are not yet approved, like Florida and I think maybe California. Do you have any sense for where those approval processes stand with CMS? And we were also curious if you had any visibility on the rural health transformation funding and what that opportunity could be.

    嘿,謝謝你的提問。我想諮詢一下醫療補助補充計劃。我們感謝大家所展現的透明度。對於尚未獲得批准的項目,例如佛羅裡達州,我想可能還有加利福尼亞州。您了解CMS的審批流程目前進展如何嗎?我們也想知道您是否了解農村醫療改革資金的情況,以及這可能帶來哪些機會。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Sure Matthew. So, our commentary on, the Florida program has been pretty consistent, and I think it's been pretty consistent because the commentary from the state of Florida has been pretty consistent. They've submitted a program, or, kind of a program.

    當然可以,馬修。所以,我們對佛羅裡達州計畫的評論一直相當一致,我認為之所以相當一致,是因為佛羅裡達州的評論也相當一致。他們提交了一份方案,或者說,某種意義上的方案。

  • Refinement they're expecting it to be approved. I think you know it would be fair to say that it's taken longer to get approved than they expected or maybe than we expected, but they've not changed their view that that ultimately the approval will be forthcoming. We've quantified the benefit to us, as best as we could and to be in that sort of $45 million to $50 million dollar range once approval is obtained. And you know we haven't recognized it, we haven't included in our guidance, but we do so, once that approval is forthcoming.

    他們預計改進後的版本會獲得批准。我想你應該明白,審批過程比他們預期的要長,也可能比我們預期的要長,但他們並沒有改變最終會獲得批准的看法。我們已經盡可能量化了這筆交易對我們的益處,一旦獲得批准,收益將在 4500 萬至 5000 萬美元之間。你知道,我們還沒有承認這一點,也沒有將其納入我們的指導方針中,但一旦獲得批准,我們就會這樣做。

  • As far as California is concerned, we've been also reasonably consistent in our comments there. We think that the California program faces more hurdles is not nearly as certain, and it's likely to be approved, it may need to be. Modified in significant ways and as a consequence while we think if it is ultimately approved it could be measurably beneficial to us we've in no way tried to quantify that or predict, how successful California will be in working with CMS, to get their program modified in a way that ultimately it would lend itself to CMS approval.

    至於加州,我們的言論也一直相當一致。我們認為加州計畫面臨的障礙更多,遠沒有那麼確定,而且它很可能獲得批准,或許也需要獲得批准。經過重大修改,雖然我們認為如果最終獲得批准,可能會對我們產生可衡量的好處,但我們從未嘗試量化或預測加州與 CMS 合作,使其計劃進行修改,最終獲得 CMS 批准,會有多大的成功。

  • Great, anything as far as the rural program goes, we, lobbied hard and worked hard, and, the structure of this program is largely up to the states, and we have worked, with the states in which we operate. We think that there could be a potential benefit to us. We acknowledge that. It's a relatively small percentage of our facilities, carry either the rural or rural referral center designation, so we don't think that the benefit ultimately would be material, but obviously, to the degree that, we could obtain any additional reimbursement, it would be positive, but not expecting it to be materially positive.

    很好,就農村計畫而言,我們進行了大量的遊說和努力,該計畫的結構很大程度上取決於各州,我們也與我們開展業務的各州進行了合作。我們認為這可能對我們有利。我們承認這一點。在我們所有機構中,只有相對較小比例的機構被認定為農村或農村轉診中心,因此我們認為最終的收益不會很大,但顯然,如果我們能夠獲得任何額外的報銷,那將是積極的,但我們並不期望它會帶來實質性的積極影響。

  • Great, thank you.

    太好了,謝謝。

  • Operator

    Operator

  • Thank you.

    謝謝。

  • Philip Chickering, Deutsche Bank.

    菲利普‧奇克林,德意志銀行。

  • Philip Chickering - Analyst

    Philip Chickering - Analyst

  • Hey, good morning, guys, and thanks for taking my question. Excluding the cash received during COVID, your leverage ratio is The lowest that I've seen for well over a decade, is there any leverage ratio where you say enough is enough and you maintain a leverage and put the rest in the repo, or do we end the year leverage down another, 10th of a turn or more?

    嘿,各位早安,感謝你們回答我的問題。除去新冠疫情期間收到的現金,你們的槓桿率是我十多年來見過的最低水準。你們認為槓桿率達到一定程度就足夠了,可以維持槓桿並將剩餘資金投入回購市場,還是應該在年底前將槓桿率再降低十分之一甚至更多?

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • So Peter, I mean, I think our, ideal, leverage is in the, [2 to 3] range, and to your point, we've been at the low end of that for a while, we've done so, with the idea that, we wanted to keep ourselves, sort of maximum flexibility to respond to, any opportunities that might arise. We still think that's, kind of a prudent position. We've been, as a pretty active acquirer of our own shares, and we'll continue, I think, to be so. We think that investing in the repurchase of our own shares is a pretty compelling investment in the current environment.

    所以彼得,我的意思是,我認為我們理想的槓桿率在 2 到 3 之間,正如你所說,我們已經有一段時間處於這個範圍的低端了,我們這樣做是出於這樣的想法:我們想讓自己保持最大的靈活性,以便應對可能出現的任何機會。我們仍然認為這是一種謹慎的立場。我們一直以來都是積極增持自身股份的公司,我認為我們還會繼續這樣做。我們認為,在當前環境下,投資回購我們自己的股票是一項非常有吸引力的投資。

  • But don't necessarily expect, to lever up dramatically in the absence of, real compelling, M&A opportunities. Don't expect our leverage to go any lower either. I would certainly make that point.

    但如果沒有真正令人信服的併購機會,就不要指望能大幅提高槓桿率。也別指望我們的槓桿率會進一步降低。我當然會提出這一點。

  • Philip Chickering - Analyst

    Philip Chickering - Analyst

  • Okay, fair enough. If I were to stay on that point, leverage keeps sort of coming down, except for sort of one large, behavioral asset out there, you guys can buy almost anything out there in the marketplace without needing to keep leverages low, I guess.

    好吧,這說得有道理。如果我堅持這個觀點,槓桿率會持續下降,除了少數大型行為資產外,你們幾乎可以在市場上購買任何東西而無需保持低槓桿率,我想是這樣。

  • Sort of follow-up with the question, I guess why keep it this low, unless there's sort of some large deals that you're looking at.

    關於這個問題,我想問一下,為什麼要把價格定得這麼低,除非你們在關註一些大宗交易。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, I mean, part of the issue in terms of being prepared or having the capacity to do M&A is you don't know when those opportunities are going to arise, you don't know how big they're going to be, etc. So, I, I'm not suggesting to you that we, we're keeping our leverage at a current level because of a, one specific anticipated, potential deal, but you know I think there are a lot of interesting, assets in the marketplace. And as we think about how those assets could fit into our strategy, again, we'd like to keep that flexibility, available to us.

    是的,我的意思是,在併購準備或能力方面,部分問題在於你不知道這些機會何時會出現,你也不知道它們的規模會有多大等等。所以,我並不是說我們維持目前的槓桿水平是因為某個特定的、預期的潛在交易,但你知道,我認為市場上有很多有趣的資產。當我們思考如何將這些資產融入我們的策略時,我們希望保持這種靈活性。

  • Philip Chickering - Analyst

    Philip Chickering - Analyst

  • Great, thanks so much. And then sort of you follow-up here on just AI like this has been a huge focus for investors obviously in the last 90 days.

    太好了,非常感謝。然後,接下來我們來談談人工智慧,顯然,在過去的 90 天裡,人工智慧一直是投資者關注的焦點。

  • A lot of people talk about rep cycle management and you talked about streamlining your full process. Can you give us like real examples about actual, efficiencies in terms of timing in cash collections and efficiencies from cost savings that this stuff can actually achieve for you guys?

    很多人都在談論銷售週期管理,而你則談到了簡化整個流程。能否舉出一些實際例子,說明這些措施在現金回收時間、節省成本等方面能為你們帶來哪些實際效率提升?

  • Marc Miller - President, Chief Executive Officer, Director

    Marc Miller - President, Chief Executive Officer, Director

  • Thanks.

    謝謝。

  • Let me jump in here. I mean, I think it's hard to pinpoint exact, numbers for you on this. I would tell you that, over the past several years, we, we've done a lot to accelerate, our pace of technology adoption, we, were a, an early, investor, with Hippocratic AI.

    我也來插一句。我的意思是,我覺得很難給你確切的數字。我想告訴大家,在過去的幾年裡,我們做了很多工作來加快科技採用的速度,我們是 Hippocratic AI 的早期投資者。

  • And we think that they are doing some terrific things in this space we're one of the primary health systems that they're working with and so what we get is we get a look at at everything they're rolling out we get an opportunity to pilot, different things and give feedback for those different things.

    我們認為他們在這一領域做得非常出色。我們是他們合作的主要醫療系統之一,因此我們有機會了解他們正在推出的所有項目,有機會試行不同的項目並就這些項目提供回饋。

  • Things, will start to pay off, in the coming, quarters and years. Some examples.

    在接下來的幾個季度和幾年裡,事情將會開始有了回報。舉例說明。

  • Steve already talked about post discharge calls, and the need, ultimately for less staff to do some of these things, and that's certainly already paying off in decreased expenses for us, but I think that if they roll out, their, various AI solutions, we're going to have a front seat to a lot of those things, and I, we've just been very impressed with where they're going and what they're doing. But other things that we're looking at right now, I mean our entire rounding process, that we, it is so important to improving quality, maintaining quality, maintaining safety, we're looking to revamp that, with different types of technology that we're testing right now.

    史蒂夫已經談到了出院後的回訪電話,以及最終需要減少人員來做這些事情,這無疑已經為我們降低了開支,但我認為,如果他們推出各種人工智能解決方案,我們將有機會近距離了解很多相關情況,我們對他們的發展方向和所做的事情印象深刻。但我們現在正在關注的其他事情,我的意思是我們的整個巡檢流程,這對提高品質、保持品質、確保安全至關重要,我們正在尋求改進它,並採用我們目前正在測試的不同類型的技術。

  • That could have a significant impact in us going into the future, not just on cost savings, but on our, increases in quality, hopefully, honestly, we would be able to impact positively, our, issues with malpractice and some things like that. So patient safety.

    這不僅會對我們未來的發展產生重大影響,而且還會提高我們的質量,希望,坦白說,我們能夠對我們處理醫療事故等問題產生積極影響。所以,要保障病人安全。

  • Technology is a big part of of what we're looking at, and then just other things like, post discharge, bringing people into the facilities, versus, with our intake process, especially in the behavioral division, so you know we think a lot of these things have great promise, it's just hard to pinpoint the exact dollars at this point.

    科技是我們關注的重點之一,此外還有其他方面,例如出院後如何將人們送入機構,以及我們的入院流程,尤其是在行為部門。因此,我們認為這些面向都很有前景,只是目前很難確定具體的資金投入。

  • Philip Chickering - Analyst

    Philip Chickering - Analyst

  • Great thanks so much.

    非常感謝。

  • Marc Miller - President, Chief Executive Officer, Director

    Marc Miller - President, Chief Executive Officer, Director

  • Alright.

    好吧。

  • Operator

    Operator

  • Thank you. Craig Hettenbach, Morgan Stanley.

    謝謝。克雷格‧赫滕巴赫,摩根士丹利。

  • Craig Hettenbach - Analyst

    Craig Hettenbach - Analyst

  • Yes, thank you. Going back to the behavioral business, as pricing starts to normalize, I know you've done a lot of work in the hiring front as you've outlined, can you just talk about the confidence in terms of getting back into more of a steady cadence on the volume side of things?

    是的,謝謝。回到行為行銷業務,隨著定價開始趨於正常化,我知道正如您所概述的,您在招聘方面做了很多工作,您能否談談在業務量方面恢復穩定節奏的信心?

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Sure, Craig, so I mean I think if you look at the cadence in 2025, we find it encouraging, we've seen sequential, incremental improvement in behavioral patient or adjusted patient day volume growth in each quarter of 2025, we ex did 2025 within what we consider to be shouting distance of this 2% to 3%.

    當然,克雷格,我的意思是,如果你看看 2025 年的節奏,我們會發現令人鼓舞,我們看到 2025 年每個季度的行為患者或調整後的患者日數量增長都有了連續、漸進的改善,我們預計 2025 年的增長將接近 2% 到 3%。

  • Target, growth range that we've set for ourselves for quite some time and have, struggled to get there, but feeling, confident, particularly when combined with, the investments in staff and headcount that we've made in 2025 and I alluded to earlier, I think that, that's what gives us the confidence that that 2% to 3% target in 2026 is, definitely achievable.

    我們為自己設定了很長一段時間的目標和增長範圍,並且一直在努力實現它,但是,我們感到有信心,特別是結合我們在 2025 年對員工和員工人數的投資(我之前也提到過),我認為,正是這些讓我們有信心,2026 年 2% 到 3% 的目標肯定可以實現。

  • Craig Hettenbach - Analyst

    Craig Hettenbach - Analyst

  • Got it. And then just as a follow-up from a capital investment perspective, any key highlights or areas of.

    知道了。然後,從資本投資的角度來看,還有哪些關鍵亮點或領域值得關注?

  • For this year.

    今年。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, I don't think it's anything extraordinary, and we're extraordinarily different, I guess I should say, in the sense that, as we said in our prepared remarks, we've got, several big new projects opening this year, a brand new De novo hospital in, on the east coast of Florida, big tower on one of our Florida West coast hospitals, a replacement facility in Southern California that will open in the next couple of months. A couple of new behavioral joint venture, hospitals opening during the year, and then I think otherwise, we're invested, I think as Mark indicated in his remarks. In, building our outpatient footprint in both businesses, but also, expanding the things that are, very core and central to our acute inpatient business, which is, emergency room capacity, surgical capacity, surgical equipment, none of that I think is terribly new or different, but, it just continues to be a focus of ours.

    是的,我不認為這有什麼特別的,而且我們應該說,我們非常不同,因為正如我們在準備好的發言稿中所說,我們今年有幾個大型新項目即將啟動,包括佛羅裡達州東海岸一家全新的De novo醫院,佛羅裡達州西海岸一家醫院的大型塔樓,以及南加州一家將在未來幾個月內開放的替代設施。今年將成立幾家新的行為合資企業,醫院也將開業,除此之外,我認為我們已經進行了投資,正如馬克在他的演講中所指出的那樣。在拓展門診業務方面,我們不僅要擴大門診業務的規模,還要擴大我們急性住院業務的核心和重要方面,例如急診室容量、手術容量、手術設備等等。我認為這些都不是全新的或特別不同的,但它們仍然是我們關注的重點。

  • Craig Hettenbach - Analyst

    Craig Hettenbach - Analyst

  • Got it. Thank you.

    知道了。謝謝。

  • Operator

    Operator

  • Thank you. Scott Fidel, Goldman Sachs.

    謝謝。Scott Fidel,高盛集團。

  • Unidentified Participant - Analyst

    Unidentified Participant - Analyst

  • Hi, this is Sammon for Scott. Just curious, could you give us an update on your overall assessment of the health care policy risks, including Medicaid work requirements and funding cuts, just your latest overall view.

    你好,我是薩蒙,替史考特問好。我很好奇,您能否更新一下您對醫療保健政策風險的整體評估,包括醫療補助工作要求和資金削減,以及您最新的整體看法。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, Sam, I don't think any of the hospital companies have made an effort to, I shouldn't say they haven't made an effort, but they haven't produced any estimates on what the impact of the Medicaid work requirements will be, beginning in 2027, because I think it's difficult to do. We don't exactly know, what the specific work requirements are going to wind up in every state. We have a sense that.

    是的,薩姆,我認為沒有任何一家醫院公司努力去估算,我不應該說他們沒有努力,但他們沒有對 2027 年開始實施的醫療補助工作要求會產生什麼影響做出任何估算,因為我認為這很難做到。我們並不確切知道每個州的具體工作要求最終會是什麼。我們有一種感覺。

  • It's likely that the people who are eliminated from the Medicaid rolls as a consequence of those requirements are likely to be less heavy utilizezers of the system, but all those variables, I think kind of remain unsolved at this point. My guess is as the year goes on, the picture will get clarified and we'll all be able to make a better estimate. But at this point, I think it's not an accident that that none of the hospital companies have really attempted to quantify with any precision what the impact of the Medicaid work requirements will be.

    由於這些要求而被從醫療補助名單中剔除的人,很可能是該系統使用頻率較低的人,但所有這些變量,我認為目前還沒有得到解決。我猜隨著時間的推移,情況會越來越明朗,我們都能做出更精確的估計。但我認為,目前還沒有任何一家醫院公司真正嘗試精確量化醫療補助工作要求的影響,這絕非偶然。

  • Operator

    Operator

  • Thank you. Benjamin Rossi, JP Morgan.

    謝謝。班傑明‧羅西,摩根大通。

  • Benjamin Rossi - Analyst

    Benjamin Rossi - Analyst

  • Hey, good morning. Thanks for taking my question. Just following up on your 2026 outlook. How are you thinking about cash flow from operations this year? I know you mentioned some of the drag last year from the increase in AR related to the Medicaid supplemental payment programs. Is that just largely timing related with new programs, or is this baseline simply becoming larger as you're receiving more from these programs? I guess just curious if there's anything more discreet we should be considering regarding cash flow generation this year.

    嘿,早安。謝謝您回答我的問題。我只是想跟進一下您對2026年的展望。您如何看待今年的經營活動現金流?我知道你去年提到過,由於醫療補助補充支付計劃導致應收帳款增加,造成了一定的拖累。這主要只是與新專案的時間安排有關,還是隨著你從這些專案中獲得更多收益,這個基準也會隨之擴大?我只是好奇,今年在現金流方面,我們是否還有什麼更謹慎的措施需要考慮。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, then, I mean, I think that if you go back and take a historic approach to this, historically.

    是的,我的意思是,我認為如果你回顧過去,從歷史的角度來看這個問題。

  • Our cash flow from operations is equal to about 75% to 80% of our operating income, less NCI, that I think, would be our view for 2026. I don't think, again, there are always sort of timing issues with receivable collection, etc. But I think, in, using that measure consistent with the historical, outcomes, I think it is a safe way to look at it.

    我們的經營活動現金流約佔營業收入的 75% 至 80%(減去少數股東權益),我認為這將是我們對 2026 年的預期。我認為,應收帳款回收等方面並非總是存在時間上的問題。但我認為,採用與歷史結果一致的衡量標準,是一種穩健的看待問題的方式。

  • Benjamin Rossi - Analyst

    Benjamin Rossi - Analyst

  • Great. And just as a follow-up on supply trends, you have a nice percentage across supply spend as a percentage of revenue during 4Q.

    偉大的。另外,關於供應趨勢,第四季供應支出佔收入的百分比相當不錯。

  • How would you characterize your current supply dynamics during the quarter? And then for 2026, I know you have a sizable degree of that supply spend in a multi-year fixed contracts, but do you see any additional room this year for any cost offsets across supply spend?

    您如何描述本季目前的供應動態?至於 2026 年,我知道你們有相當一部分供應支出是透過多年固定合約實現的,但你們認為今年是否還有空間在供應支出方面進行成本抵銷呢?

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, I mean, I think as we indicated in our prepared remarks, supply costs were probably the most effectively controlled of all the expense categories in 2025. We're not necessarily anticipating, significant pressure points. I think, it turned out that, tariffs, which were a concern potentially, maybe a year ago have not really impacted our industry in a measurable way, and I don't think we we anticipate that they will. There's always, opportunities for us to continue to be more efficient there. Most of those opportunities I would describe as opportunities to work with our clinicians in their, supply preference, particularly for, the high costs items, and so we remain focused in the area, but, certainly as we think about any potential areas of cost exposure in 2026, supplies are not high on that list.

    是的,我的意思是,我認為正如我們在準備好的演講稿中所指出的那樣,在2025年,供應成本可能是所有支出類別中控制得最有效的。我們可能不會預料到重大的壓力點。我認為,事實證明,關稅(也許一年前它可能是一個令人擔憂的問題)並沒有對我們的行業產生可衡量的影響,而且我認為我們預計它們不會產生影響。我們總有機會持續提高這方面的效率。我將大部分機會描述為與我們的臨床醫生合作,了解他們的供應偏好,特別是高成本物品的供應偏好,因此我們將繼續關注這一領域,但可以肯定的是,當我們考慮 2026 年任何潛在的成本風險領域時,物資供應並不在優先考慮之列。

  • Great, thanks for the comments.

    太好了,謝謝你的評論。

  • Operator

    Operator

  • Thank you. Michael Ha, Baird.

    謝謝。Michael Ha,貝爾德。

  • Michael Ha - Senior Reseach Analyst

    Michael Ha - Senior Reseach Analyst

  • Thank you. On behavioral health over the past couple of years we've been very vocal about the benefit of DPPs, how they've made, excuse me, Medicaid volumes and behavioral health much more profitable, and because of that there's been a strong emphasis on driving more of these volumes. We've seen it materialize through your. Sellar behavioral health pricing performance. I know today you mentioned expectations of that to slightly normalize in '26, but that said, the DPP challenges are still here. They don't come down until starting '28, so no immediate shift.

    謝謝。在過去幾年裡,我們在行為健康領域大力宣傳 DPP 的好處,以及它們如何讓醫療補助業務量和行為健康業務變得更加有利可圖,正因如此,我們才如此重視推動這些業務量的成長。我們已經透過你看到了它的實現。Sellar行為健康定價績效。我知道你今天提到預計這種情況會在 2026 年略有好轉,但即便如此,DPP 的挑戰仍然存在。它們要到 28 年開始才會下架,所以不會立即改變。

  • So looking forward as we enter '28, can you talk about your thoughts on the durability of long-term pricing? Should we think about '28 as sort of that. Starting year, more incremental changes lower. Also, how might you plan to potentially shift your Medicaid volume strategy over that time? Could that impact your long-term 2 to 3 volume target? And would any of those declines maybe be met with and offset by your outpatient business, maybe more commercial mix through that end? Sorry, a lot of questions. Overall, how are you thinking about all these different pieces?

    展望2028年,您能否談談您對長期價格穩定性的看法?我們是否應該把 28 年看成是那樣呢?從年初開始,增量變動會更小。另外,您計劃如何在此期間調整您的醫療補助計劃規模策略?這是否會影響您長期2到3倍的成交量目標?那麼,您的門診業務,或透過增加門診業務的商業組合,能否抵銷這些下滑的影響呢?不好意思,問題有點多。總的來說,你對所有這些不同的部分有什麼看法?

  • Thank you.

    謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, so it's a very comprehensive question, Michael, and I think in some respects, you answered some of the questions you asked. I will say, as you noted that while DPP reimbursement is scheduled to begin to be reduced in 2028, we still have. Several years, a couple of years ahead of us where, the reimbursement remains intact and as those who, follow our disclosures know, it's actually been increasing over the last couple of years as either new programs are being approved or existing programs are expanding or Medicaid utilization is expanding, and so, we intend to largely try and take advantage of that benefit while it's out there, while at the same time.

    是的,邁克爾,這是一個非常全面的問題,我認為在某些方面,你已經回答了你提出的一些問題。正如您所指出的,雖然 DPP 報銷計劃從 2028 年開始減少,但我們仍然有…未來幾年,也就是幾年內,報銷政策仍然有效。正如那些關注我們披露資訊的人所知,過去幾年,隨著新項目的獲批、現有項目的擴展或醫療補助使用量的增加,報銷額實際上一直在增長。因此,我們打算在政策有效期間盡可能地利用這項福利。

  • Thinking about and planning for, a scenario in which, that Medicaid business is not as profitable as it might be today, and as you suggested, one of the major ways we we'll do that is on the outpatient side. I mentioned earlier in response to a different question that outpatient margins tend to be better than inpatient margins, and one of the reasons for that. Is the outpatient payer mix tends to be much more weighted to commercial than it is to Medicaid, so, yeah, as we continue to grow, and focus on our outpatient initiatives, which both Mark and I have spent some time on describing, I think that will be a natural hedge to some degree, against, the DPP reduction risk that faces us in a few years.

    考慮到醫療補助業務可能不如現在這樣有利可圖,我們正在考慮併計劃應對這種情況,正如您所建議的,我們將採取的主要措施之一是在門診方面。我之前在回答另一個問題時提到過,門診利潤往往比住院利潤更好,其中一個原因是…門診支付方的組成往往商業保險比醫療補助更佔比,所以,是的,隨著我們不斷發展壯大,並專注於我們的門診計劃(我和馬克都花了一些時間來描述這些計劃),我認為這將在一定程度上自然地對沖我們幾年後面臨的 DPP 削減風險。

  • Operator

    Operator

  • Thank you, Ryan Langston, TD Cowen.

    謝謝你,Ryan Langston,TD Cowen。

  • Ryan Langston - Analyst

    Ryan Langston - Analyst

  • Great, thanks for squeezing me in. Behavioral FTEs grew, I believe, 3.5% to 4% in 2025. You've talked in the past about particular job classes being more difficult to fill. I guess how should we think about that 3.5% to 4% growth in some of those more difficult categories of the growth rate and how that translates into the 2% to 3% outlook for behavioral health growth? Thanks.

    太好了,謝謝你們擠出時間幫我。我認為,到 2025 年,行為學 FTE 將成長 3.5% 至 4%。你之前曾談到某些特定職位類別更難招募到合適的人。我想我們應該如何看待某些較難預測的成長率類別中 3.5% 到 4% 的成長率,以及這如何轉化為行為健康領域 2% 到 3% 的成長預期?謝謝。

  • Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

    Steve Filton - Chief Financial Officer, Executive Vice President, Secretary

  • Yeah, and we've made the point in the past, Ryan, that the behavioral staffing challenges are really different in every market and in some markets we're challenged with hiring sufficient nurses in other markets it could be therapists and in other markets. It could be, the non-licensed professionals, the people that we call mental health technicians. It really varies, and, frankly, in many markets, we, we're fully staffed and don't face those challenges.

    是的,瑞安,我們過去也指出過,行為健康從業人員配備方面的挑戰在每個市場都截然不同,有些市場面臨的挑戰是招聘足夠的護士,有些市場面臨的挑戰是招聘治療師,還有一些市場面臨的挑戰是招聘治療師。也可能是那些沒有執照的專業人員,也就是我們所謂的心理健康技術人員。情況確實因市場而異,坦白說,在許多市場,我們人員配備齊全,並沒有面臨這些挑戰。

  • So, I don't necessarily have a breakdown, in front of me at the moment in terms of. The headcount increase in 2025, exactly which, staffing categories that involved my guess is it's sort of across the board because it, we hired where we needed to in each individual market, but I think the important thing from our perspective is we made a conscious decision in 2025.

    所以,就目前而言,我眼前不一定有崩潰的情況。2025 年的員工人數增加,具體增加哪些人員類別,我猜是全面增加的,因為我們在每個市場都根據需要進行了招聘,但我認為從我們的角度來看,重要的是我們在 2025 年做出了一個深思熟慮的決定。

  • To really ramp up the hiring in those markets where staffing vacancies were an obstacle, to further volume growth and, now having hired and filled not all but many of those positions, I think it gives us, greater confidence in meeting that 2% to 3% patient day volume growth target in 2026.

    為了真正加大在人員空缺成為障礙的市場的招募力度,以進一步促進業務量成長,現在我們已經招募並填補了其中大部分職位,雖然不是全部,但我認為這讓我們更有信心在 2026 年實現 2% 到 3% 的患者日業務量增長目標。

  • Operator

    Operator

  • Thank you, and I would like to turn the call back over to Darren for closing remarks. Please go ahead.

    謝謝,現在我把電話交還給達倫,請他做總結發言。請繼續。

  • Darren Lehrich - Vice President, Investor Relations

    Darren Lehrich - Vice President, Investor Relations

  • Thanks, Lisa.

    謝謝你,麗莎。

  • Thank you everyone for participating in today's call and for your interest in UHS.

    感謝各位參加今天的電話會議,也感謝各位對UHS的關注。

  • Have a great rest of your day.

    祝您今天餘下的時間過得愉快。

  • Operator

    Operator

  • This does conclude today's conference call. Thank you so much for joining. You may now disconnect.

    今天的電話會議到此結束。非常感謝您的參與。您現在可以斷開連線了。